A germline activating mutation in the RET protooncogene occurs in nearly all patients with hereditary MTC, whereas a somatic RET mutation occurs in approximately 50% of sporadic tumors [1,2,3,4,5]. This evidence concerns the gene RET and medullary thyroid gland carcinoma.